Prevalence of Bacterial Urinary Tract Infection Among Patients With Type 2 Diabetes Mellitus on Sodium-Glucose Cotransporter-2 Inhibitors: A Prospective Real-World Setting Study

Pankaj Ferwani, Aasim Maldar, Nishitkumar Shah, Phulrenu Chauhan, Manoj Chadha

Department of Endocrinology, P. D. Hinduja National Hospital and Medical Research Centre, Mumbai, Maharashtra State, India

Abstract

Background. Genitourinary tract infections, mycotic as well as bacterial, as defined by clinical symptoms, are one of the common adverse effects associated with the use of sodium-glucose cotransporter-2 inhibitors (SGLT2i) in type 2 diabetes mellitus (T2DM) patients in clinical trials. However, Indian data in terms of the prevalence of culture-proven bacterial type of urinary tract infection (UTI), and the causative organism is limited.

Objective. This study aimed to determine the prevalence and causative agents of bacterial UTI among patients with T2DM on SGLT2i.

Methodology. This was a prospective longitudinal study involving all patients with T2DM who were prescribed with SGLT2i, uncontrolled on other oral anti-diabetic medications, from June 2019 to February 2020. Prevalence of bacterial UTI was evaluated at baseline and 12 weeks after initiation of SGLT2i.

Results. A total of 80 patients were started on SGLT2i. One female patient on canagliflozin had significant asymptomatic bacteriuria and the causative agent was Acinetobacter baumannii. One male patient on dapagliflozin had symptomatic UTI with negative urine culture study. Four patients developed genital mycotic infection.

Conclusion. In this real-world study, SGLT2i as a class, was well tolerated with favorable safety profile, and risk of developing significant bacteriuria and/or symptomatic UTI was minimal.

Key words: SGLT2i, type 2 diabetes mellitus, UTI, significant bacteriuria

INTRODUCTION

Diabetes mellitus is the most common endocrine disease of the century. It is discouraging to contemplate the burden Type 2 diabetes may impose on India in the future.

The significant morbidity and mortality, high rates of complications and the cost of therapy can have a huge socio-economic impact on individuals and families.12 The treatment of T2DM in India has been traditionally based on metformin, sulfonylureas, voglibose and insulin. However, newer agents such as dipeptidyl peptidase 4 inhibitors (DPP4i), sodium-glucose cotransporter-2 inhibitors (SGLT2i), and glucagon-like peptide-1 (GLP1) receptor agonists promise a substantial benefit in the treatment of naïve, as well as uncontrolled diabetes patients.24 Inhibition of SGLT-2 offers potential add-on benefits of weight loss, blood pressure (BP) reduction, and cardiovascular-renal benefits, with a low risk of hypoglycemia.5,6

Dapagliflozin, canagliflozin, empagliflozin and remogliflozin are currently available in India. They have been approved for the treatment of T2DM as monotherapy and as second- or third-line agents in combination with other therapeutic options for diabetes. This drug class may be used at any stage of T2DM owing to its novel insulin-independent mechanism of action, provided the renal function is above a certain threshold.25,26 Genitourinary tract (GUT) infections are the most common adverse effect of SGLT2i use in clinical trials.2,3,4 People with diabetes are at increased risk for GUT infections due to glucosuria, bacterial adherence to uroepithelium and immune dysfunction.12

The prevalence of bacterial urinary tract infections (UTI), defined by clinical symptoms, among patients with T2DM on SGLT2i is 9%.10 There is limited Indian data on the prevalence of culture-proven bacterial UTI, type of UTI, and the causative organism in T2DM patients on SGLT2i.13 Real-world data will help ascertain if the safety results...
of SGLT2i seen in clinical trials can be extrapolated to clinical practice. No prospective studies have specifically addressed this issue in India.

Hence, we performed this study to assess the prevalence of bacterial UTI in patients with T2DM on SGLT2i in Indian patients in the ambulatory setting.

METHODOLOGY

This was a prospective longitudinal study conducted in a tertiary care center among patients with T2DM who were started on SGLT2i uncontrolled on other oral antidiabetic medications [glycosylated hemoglobin (HbA1c) >7%] and/or fasting venous plasma glucose (FPG) >120 mg/dL. Patients less than 18 years of age, with estimated glomerular filtration rate (eGFR) <45 ml/min/1.73m², pregnant/lactating women, and evidence of UTI within the past 3 months were excluded. Patients were included after giving them complete relevant information and obtaining a written consent.

The baseline FPG, post-lunch venous plasma glucose (PPG) and HbA1c were recorded. Urine sample for bacterial culture was collected at baseline prior to initiation of SGLT2i. Patients were prescribed any one of the 4 available SGLT2i – dapagliflozin, empagliflozin, canagliflozin or remogliflozin.

Patients were educated about maintaining genital and perineal hygiene. Instructions were given about washing of genital organs with clean water after urination and defecation and routine use of hygienic wipes. Women were advised to wash from front to back, while uncircumcised males were counseled to retract the prepuce before cleaning. Patients were advised to use mild soap if required and avoid alcohol-based disinfectants for washing.

Patients who developed symptoms of UTI at any time during the 12-week period were advised to report to the clinic immediately and a midstream urine sample for bacterial culture was collected as necessary. After 12 weeks of SGLT2i therapy. Analysis of adverse effect profile (bacterial UTI) was done as a class effect, rather than an individual drug effect.

Statistical analysis was done using “R software 3.5.1.” Continuous variables were expressed as mean ± standard deviation (SD). Results of qualitative variables such as fever, frequency, urgency, dysuria, significant bacteriuria and genital mycotic infection symptoms were expressed as frequency and percentages.

The study was approved by the Institutional Ethics Committee. All the patients' details were kept confidential and participants' identity was coded for further analysis.

RESULTS

A total of 80 T2DM patients (47 males and 33 females) were initiated on SGLT2i over a period of 3 months. Four patients discontinued the drug (1 patient underwent prostate surgery, 1 patient had inguinal hernia surgery and 2 patients had subjective non-specific weakness) and 1 patient could not be contacted. At 12 weeks, 75 patients were evaluated.

The baseline characteristics of patients is shown in Table 1. Majority (50 out of 80, 62.5%) of participants were 46-65 years (mean 52.44 ± 10.24 years). The duration of diabetes was more than 5 years in 52 (82.7%) participants, none had BMI > 35 kg/m². The body mass index (BMI) was >25 kg/m² in 62 (82.7%) participants, none had BMI > 35 kg/m² (mean 26.99 ± 2.24 kg/m²).

Table 1. Baseline characteristics

| Characteristic | Value          |
|---------------|----------------|
| Mean age (years) ± SD | 52.44 ± 10.24 |
| Gender (Male: Female) | 47:33          |
| Mean duration of T2DM (years) ± SD | 8.95 ± 4.84 |
| Mean HbA1c (%) ± SD | 8.71 ± 0.99   |
| Mean BMI (kg/m²) ± SD | 26.99 ± 2.24  |
Of the 75 participants who completed the study, 36 (48%) were on dapagliflozin 10 mg daily; 13 (17.3%) on empagliflozin 10 mg daily; 13 (17.3%) on empagliflozin 25 mg daily; 8 (10.6%) on remogliflozin 100 mg twice a day; and 5 (6.6%) were on canagliflozin 100 mg daily (Figure 1).

One (1.3%) female patient who received canagliflozin had significant asymptomatic bacteriuria at 12 weeks. The causative organism identified was *Acinetobacter baumannii* (Table 2). One (1.3%) male patient had symptomatic UTI with dysuria 4 weeks after starting dapagliflozin. Urine culture of the patient was negative. (Table 2). One (3.3%) male patient had symptomatic UTI with dysuria 4 weeks after starting dapagliflozin. Urine culture of the patient was negative. (Table 2). One (1.3%) female patient who received canagliflozin had significant asymptomatic bacteriuria at 12 weeks of SGLT2i therapy. The patient was taking canagliflozin.

The prevalence of significant bacteriuria reported in the study conducted by Mathieu,\(^{19}\) (1%), and was higher than in the studies from India by Sosale\(^{20}\) and Ghosh,\(^{21}\) where it was 0% and 0.01% respectively.

The likely explanation for the low rate of genital mycotic infections among our patient population may be good genital hygiene, knowledge of side effects and precautions taken while on SGLT2i.

The strengths of our study are that it is a real-world prospective study done in a heterogeneous urban population and the diagnosis of bacterial UTI was based on urine culture done on all patients, regardless of symptoms. We acknowledge that the study period of 12 weeks was relatively short, and UTI as an outcome with more prolonged therapy require further assessment. Lack of a control group and lack of routine urinalysis and microscopy were the limitations of our study. Also, due to small number of outcomes in our study, it is not possible to comment on the choice of specific drug from the SGLT2i drug class.

**DISCUSSION**

The post-hoc power of our study to calculate the prevalence of bacterial UTI and symptomatic UTI was ~80%. The reported prevalence of significant bacteriuria in T2DM patients at baseline, and in control groups ranged from 7.7% to 26%.\(^{10,14,15}\) In our study, the overall prevalence of significant asymptomatic bacteriuria at 12 weeks of SGLT2i treatment was 1.3%. The patient was on canagliflozin. The prevalence of significant bacteriuria reported in the study conducted by Nicolle et al. was 7.7% at baseline and 6.4% at 12 weeks after taking canagliflozin with no dose dependency.\(^{14}\) The lack of association of bacteriuria or symptomatic UTI with SGLT2i therapy may be because glucosuria is not the only risk factor for symptomatic UTIs or bacteriuria, and other factors such as hyperglycemia, presence of bladder autonomic neuropathy and urinary tract abnormalities can influence development of symptomatic UTIs or bacteriuria.\(^{9,12}\)

The prevalence of symptomatic UTI was 1.3% in our study. The patient was taking dapagliflozin 10 mg daily. The prevalence of symptomatic UTI we report was lower than studies conducted by List,\(^{26}\) Bode\(^{27}\) and Rosenstock\(^{28}\) where it was found in 5 to 12%, 5.8 to 8.1%, and 4% patients respectively. The prevalence was similar to the study conducted by Mathieu,\(^{19}\) (1%), and was higher than in the studies from India by Sosale\(^{20}\) and Ghosh,\(^{21}\) where it was 0% and 0.01% respectively.

In our study, the prevalence of genital mycotic infection was 5.3%. The same prevalence was observed in the study of Wan Seman et al.\(^{22}\) The prevalence was less than the studies conducted by Bode\(^{17}\) and Aggarwal,\(^{23}\) where it was 18.6% and 26% respectively; and was more than the study conducted by Kohler,\(^{24}\) where it was 1% amongst the canagliflozin treated patients.

The prevalence of significant asymptomatic bacteriuria among patients on SGLT2i with regards to the development of significant bacteriuria and/or UTI.

**CONCLUSIONS**

In this real-world study, the risk of developing significant bacteriuria and/or symptomatic UTI was minimal in patients with T2DM on SGLT2i. Furthermore, the risk of clinically diagnosed genital mycotic infection was also low. SGLT2i was well tolerated with a favorable safety profile. Additional adequately powered longitudinal randomized real-world studies using urine culture and urine routine analysis may be undertaken to confirm the safety of SGLT2i with regards to the development of significant bacteriuria and/or UTI.

The genitourinary infections and bacterial UTI may be preventable if patients are diligently educated about maintaining good genital hygiene.
As there was only one patient with asymptomatic bacteriuria, and another patient with dysuria with a negative urine-culture, it is not possible to comment on the choice of specific drug from the SGLT2i drug class.

Statement of Authorship
All authors certified fulfillment of ICMJE authorship criteria.

Author Contributions Statement
PF conceived the study, developed the methodology, applied statistical techniques to synthesize the study data, conducted investigation, curated the data, prepared the original draft of the manuscript, prepared data presentation; AM validated research outputs, analyzed study data, provided study materials, wrote, reviewed and edited the manuscript, supervised the research activity; PC and MC provided study materials, wrote, reviewed and edited the manuscript, supervised the research activity.

Author Disclosure
The authors declared no conflict of interest.

Funding Source
The study was funded by National Education Society (Medical Research Centre) of P. D. Hinduja National Hospital.

References
1. Kaveeshwar SA, Cornwall J. The current state of diabetes mellitus in India. Australas Med J. 2014;7(1):45-8. PMID: 24567766. PMCID: PMC3920109. https://doi.org/10.4066/AMJ.2013.197.
2. Yesudian P, Grigoriadis M, Visintin E, Ferrario A. The economic burden of diabetes in India: A review of the literature. Global Health. 2014;10:80. PMID: 25443136. PMCID: PMC4279984. https://doi.org/10.1186/s12992-014-0080-x.
3. George RE, Joseph S. A review of new treatment approaches for type-2 diabetes: Focusing safety and efficacy of incretin based therapy. Saudi Pharm J. 2014;22(5):403-10. PMID: 25473328. PMCID: PMC4246366. https://doi.org/10.1016/j.jsps.2013.05.005.
4. Kaleta S, Sahay R, Gupta V. Sodium glucose co-transporter 2 (SGLT2) inhibition and ketogenesis. Indian J Endocrinol Metab. 2015 Jul-Aug;19(4):524-8. PMID: 26180770. PMCID: PMC481661. https://doi.org/10.4103/2230-8015.175899.
5. Rabiee A, Kheirandish M, Esteghamati A. Cardiovascular and renal benefits of SGLT2 inhibitors: A Narrative Review. Int J Endocrinol Metab. 2019;17(2):e84335. PMID: 31372172. PMCID: PMC6628166. https://doi.org/10.5812/ijem.84335.
6. Ribola FA, Camargo JB, Schouest JE, De Toni VF, Medeiros VH, Feder D. Effects of SGLT2 inhibitors on weight loss in patients with type 2 diabetes mellitus. Eur Rev Med Pharmacol Sci. 2017;21(1):199-211. PMID: 28121357.
7. Inaguchi SE, Bergren ML, Buse JB, et al. Management of hyperglycemia in type 2 diabetes: A patient-centered approach: Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2012;35:G4-79. PMID: 22517736. PMCID: PMC3357214. https://doi.org/10.2337/dctd-12-0413.
8. Zimman B, Wanner C, Lachin JM, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373(22):2117-28. PMID: 26378978. https://doi.org/10.1056/NEJMoa1504720.
9. Nitzan O, Elias M, Chauan B, Saliba W. Urinary tract infections in patients with type 2 diabetes mellitus: review of prevalence, diagnosis, and management. Diabetes Metab Syndr Obes. 2015;8:129-36. PMID: 25759992. PMCID: PMC4346284. https://doi.org/10.2147/DMSO.S51792.
10. Liu J, Li L, Li S, Jia P, Deng K, Chen W, Sun X. Effects of SGLT2 inhibitors on UTIs and genital infections in type 2 diabetes mellitus: A systematic review and meta-analysis. Sci Rep. 2017;7(1):2824. PMID: 28588220. PMCID: PMC5460243. https://doi.org/10.1038/s41598-017-02735-w.
11. Hsia DS, Grove O, Celalu WT. An update on sodium-glucose co-transporter-2 inhibitors for the treatment of diabetes mellitus. Curr Opin Endocrinol Diabetes Obes. 2017;24(1):73-79. PMID: 27989586. PMCID: PMC6028352. https://doi.org/10.1097/MED.0000000000000311.
12. Casqueiro J, Casqueiro J, Alves C. Infections in patients with diabetes mellitus: A review of pathogenesis. Indian J Endocrinol Metab. 2012;16 Suppl 1(1):527-36. PMID: 22701840. PMCID: PMC3354930. https://doi.org/10.4103/2230-8210.94253.
13. Gill HK, Kaur P, Mahendru S, Mittal A. Adverse effect profile and effectiveness of sodium glucose co-transporter 2 inhibitors (SGLT2) - A prospective real-world setting study. Indian J Endocrinol Metab. 2019;23(1):50-5. PMID: 31016153. PMCID: PMC4646693. https://doi.org/10.4103/ijem.IJEM_566_18.
14. Nicolle LE, Capuano G, Ways K, Usiskin K. Effect of canagliflozin, a sodium-glucose co-transporter 2 (SGLT2) inhibitor, on bacteriuria and urinary tract infection in subjects with type 2 diabetes enrolled in a 12-week, phase 2 study. Curr Med Res Opin. 2012;28:1167-71. PMID: 22548646. https://doi.org/10.1185/03007995.2012.689956.
15. Renko M, Tapanainen P, Tossavainen P, Pokka T, Uhari M. Meta-analysis of the significance of asymptomatic bacteriuria in diabetes. Diabetes Care. 2013;36(4):1230-5. PMID: 2395688. PMCID: PMC3005460. https://doi.org/10.2337/dc12-0421.
16. List JF, Woo V, Morales E, Tang W, Fiedorek FT. Sodium-glucose cotransporter inhibition with dapagliflozin in type 2 diabetes. Diabetes Care. 2009 Apr;32(4):650-7. PMID: 19114612. PMCID: PMC2660449. https://doi.org/10.2337/dc12-0421.
17. Bode B, Stenløf K, Sullivan D, Fung A, Usiskin K. Efficacy and safety of canagliflozin treatment in older subjects with type 2 diabetes mellitus: A randomized trial. Horm Res Pract. 2015;2013(2):72-84. PMID: 2360739. https://doi.org/10.3810/hp.2013.04.1020.
18. Rosenstock J, Seman LJ, Jelaska A, Hantel S, Pinnetti S, Hach T, Woerle HJ. Effectiveness of empagliflozin, a sodium glucose co-transporter 2 (SGLT2) inhibitor, as add-on to metformin in type 2 diabetes with mild hyperglycaemia. Diabetes Obes Metab. 2013;15(12):1154-60. PMID: 23906374. https://doi.org/10.1111/diab.12185.
19. Mathieu C, Ranetti AE, Li D, et al. Randomized, double-blind, phase 3 trial of triple therapy with dapagliflozin add-on to saxagliptin plus metformin in type 2 diabetes. Diabetes Care. 2015;38(11):2009-17. PMID: 26246458. https://doi.org/10.2337/dc15-0779.
20. Sovale B, Sosale AR, Kumar PM, Joshi SR. A prospective analysis of the efficacy and safety of sodium glucose co-transporter-2 inhibitors: Real world evidence from clinical practice in India. J Assoc Physicians India. 2016;64(9):40-4. PMID: 27762514.
21. Ghosh A, Gupta R, Singh P, Dutta A, Misra A. Sodium-glucose co-transporter-2 inhibitors in patients with type 2 diabetes in North India: A 12-month prospective study in real-world setting. Int J Clin Pract. 2016;70(2):1237. https://doi.org/10.1111/ijcp.12327.
22. Wan Seman WJ, Kori N, Rajoo S, et al. Switching from sulphonylurea to a sodium-glucose co-transporter2 inhibitor in the fasting month of Ramadan is associated with a reduction in hyperglycaemia. Diabetes Obes Metab. 2016;18(6):628-32. PMID: 26889911. https://doi.org/10.1111/diab.12649.
23. Aggarwal A, Wadhwa R, Kapoor D, Khanna R. High prevalence of genital mycotic infections with sodium-glucose co-transporter 2 inhibitors among indian patients with type 2 diabetes. Indian J Endocrinol Metab. 2019;23(3):9-13. PMID: 31061146. PMCID: PMC4446664.
24. Kohler S, Salassi A, Hantel S, et al. Safety and tolerability of empagliflozin in patients with type 2 diabetes. Clin Ther. 2016;38(6):1299-313. PMID: 27085855. https://doi.org/10.1016/j.clinthera.2016.03.031.